Jong Chul Park

21PUBLICATIONS
128CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|May 13, 2026
Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig.

|Feb 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

Jong Chul Park, David Berz, Manish R Sharma

|Jan 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.

Jong Chul Park, David Berz, Manish R Sharma

|Sep 29, 2025
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.

Jong Chul Park, Brendan Curti, Marcus Butler

|Sep 26, 2025
Novel Therapeutic Development for Nasopharyngeal Carcinoma.

Jongwoo Kim, Yunjoo Lee, Seoin Kim

|May 20, 2025
Direct Comparison of Alternative Blood-Based Approaches for Early Detection and Diagnosis of HPV-Associated Head and Neck Cancers.

Michael E Bryan, Ling Aye, Dipon Das

Pageof 4

Frequent Collaborators

4 joint publications

Lori Wirth

3 joint publications

Peter M Sadow

3 joint publications

William C Faquin

3 joint publications

Ross Merkin